+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

T Cell Immunotherapy Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026

  • ID: 5316696
  • Report
  • March 2021
  • Region: Global
  • 100 Pages
  • Infinium Global Research

FEATURED COMPANIES

  • Adaptimmune Therapeutics
  • Autolus
  • Bluebird Bio
  • CARsgen Therapeutics
  • Celgene
  • Cellectis

The report on the global T-cell immunotherapy market provides qualitative and quantitative analysis for the period from 2018 to 2026. The report predicts the global T cell immunotherapy market to grow with a CAGR of 15.70% over the forecast period from 2020-2026. The study on the T-cell immunotherapy market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2018 to 2026.






The report on the T-cell immunotherapy market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global T-cell immunotherapy market over the period of 2018 to 2026. Moreover, the report is a collective presentation of primary and secondary research findings.


Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market, and opportunities for the new entrants in the global T cell immunotherapy market over the period of 2018 to 2026. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.


Report Findings


1) Drivers
The growing occurrence of cancer in both children as well as in adults 


2) Restraints
Extend waiting period for administration of t-cell immunotherapy is expected to hamper the market growth


3) Opportunities
The rapidly increasing research and development activities and technological advancement in cancer treatment 


Research Methodology


A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include 
1. Key Opinion Leaders associated
2. Internal and External subject matter experts 
3. Professionals and participants from the industry 


The primary research respondents typically include 
1. Executives working with leading companies in the market under review 
2. Product/brand/marketing managers 
3. CXO level executives 
4. Regional/zonal/ country managers 
5. Vice President level executives. 


B) Secondary Research 
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.


The secondary sources of the data typically include 
1. Company reports and publications 
2. Government/institutional publications 
3. Trade and associations journals 
4. Databases such as WTO, OECD, World Bank, and among others. 
5. Websites and publications by research agencies


Segment Covered
The global T cell immunotherapy market is segmented on the basis of mechanism of action, type of therapy, and product class. 


The Global T cell immunotherapy market by Mechanism of Action


  • Active Immunotherapy 
  • Passive Immunotherapy

The Global T cell immunotherapy market by Type of Therapy 


  • CAR-T
  • TCR
  • TIL

The Global T cell immunotherapy market by Product Class


  • Monoclonal Antibodies
  • Oncolytic Virus Therapy
  • Bispecific Antibodies
  • Cytokines

Company Profiles
The companies covered in the report include


  • Adaptimmune Therapeutics
  • Bluebird Bio
  • Innovative Cellular Therapeutics
  • Novartis
  • Sinobioway Cell Therapy
  • Cellectis
  • CARsgen Therapeutics
  • Autolus
  • Celgene

Others


What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the T cell immunotherapy market.
2. Complete coverage of all the segments in the T cell immunotherapy market to analyze the trends, developments in the global market and forecast of market size up to 2026.
3. Comprehensive analysis of the companies operating in the global T cell immunotherapy market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify."


Frequently Asked Questions about the T-Cell Immunotherapy Market

What is the estimated value of the T-Cell Immunotherapy Market?

The T-Cell Immunotherapy Market was estimated to be valued at $3188.9 Million in 2020.

What is the growth rate of the T-Cell Immunotherapy Market?

The growth rate of the T-Cell Immunotherapy Market is 15.7%, with an estimated value of $7648.9 Million by 2026.

What is the forecasted size of the T-Cell Immunotherapy Market?

The T-Cell Immunotherapy Market is estimated to be worth $7648.9 Million by 2026.

Who are the key companies in the T-Cell Immunotherapy Market?

Key companies in the T-Cell Immunotherapy Market include Adaptimmune Therapeutics, Autolus, Bluebird Bio, CARsgen Therapeutics, Celgene, Cellectis, Innovative Cellular Therapeutics and Sinobioway Cell Therapy.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adaptimmune Therapeutics
  • Autolus
  • Bluebird Bio
  • CARsgen Therapeutics
  • Celgene
  • Cellectis

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches


2. Executive Summary
2.1. T-Cell Immunotherapy Market Highlights
2.2. T-Cell Immunotherapy Market Projection
2.3. T-Cell Immunotherapy Market Regional Highlights


3. Global T-Cell Immunotherapy Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Analysis of COVID-19 impact on the T-Cell Immunotherapy Market
3.4. Porter's Five Forces Analysis
3.5. Growth Matrix Analysis
3.5.1. Growth Matrix Analysis by Mechanism of Action
3.5.2. Growth Matrix Analysis by Type of Therapy
3.5.3. Growth Matrix Analysis by Product Class
3.5.4. Growth Matrix Analysis by Region
3.6. Value Chain Analysis of T-Cell Immunotherapy Market


4. T-Cell Immunotherapy Market Macro Indicator Analysis
5. Global T-Cell Immunotherapy Market by Mechanism of Action
5.1. Active Immunotherapy
5.2. Passive Immunotherapy


6. Global T-Cell Immunotherapy Market by Type of Therapy
6.1. CAR-T
6.2. TCR
6.3. TIL


7. Global T-Cell Immunotherapy Market by Product Class
7.1. Monoclonal Antibodies
7.2. Oncolytic Virus Therapy
7.3. Bispecific Antibodies
7.4. Cytokines


8. Global T-Cell Immunotherapy Market by Region 2020-2026
8.1. North America
8.1.1. North America T-Cell Immunotherapy Market by Mechanism Of Action
8.1.2. North America T-Cell Immunotherapy Market by Type Of Therapy
8.1.3. North America T-Cell Immunotherapy Market by Product Class
8.1.4. North America T-Cell Immunotherapy Market by Country
8.2. Europe
8.2.1. Europe T-Cell Immunotherapy Market by Mechanism Of Action
8.2.2. Europe T-Cell Immunotherapy Market by Type Of Therapy
8.2.3. Europe T-Cell Immunotherapy Market by Product Class
8.2.4. Europe T-Cell Immunotherapy Market by Country
8.3. Asia-Pacific
8.3.1. Asia-Pacific T-Cell Immunotherapy Market by Mechanism Of Action
8.3.2. Asia-Pacific T-Cell Immunotherapy Market by Type Of Therapy
8.3.3. Asia-Pacific T-Cell Immunotherapy Market by Product Class
8.3.4. Asia-Pacific T-Cell Immunotherapy Market by Country
8.4. RoW
8.4.1. RoW T-Cell Immunotherapy Market by Mechanism Of Action
8.4.2. RoW T-Cell Immunotherapy Market by Type Of Therapy
8.4.3. RoW T-Cell Immunotherapy Market by Product Class
8.4.4. RoW T-Cell Immunotherapy Market by Sub-region


9. Company Profiles and Competitive Landscape
9.1. Competitive Landscape in the Global T-Cell Immunotherapy Market
9.2. Companies Profiled
9.2.1. Adaptimmune Therapeutics
9.2.2. Bluebird Bio
9.2.3. Innovative Cellular Therapeutics
9.2.4. Novartis
9.2.5. Sinobioway Cell Therapy
9.2.6. Cellectis
9.2.7. CARsgen Therapeutics
9.2.8. Autolus ltd
9.2.9. Celgene
9.2.10. Others
Note: Product cover images may vary from those shown
  • Adaptimmune Therapeutics
  • Autolus
  • Bluebird Bio
  • CARsgen Therapeutics
  • Celgene
  • Cellectis
  • Innovative Cellular Therapeutics
  • Novartis
  • Sinobioway Cell Therapy
Note: Product cover images may vary from those shown